Serum OxLDL-β2GPI Complex Reflects Metabolic Syndrome and Inflammation in Adipose Tissue in Obese

Overview

Journal Int J Obes (Lond)

Specialty Endocrinology

Date 2017 Oct 31

PMID 29081508

Citations 1

Authors

M Siklova

M Koc

L Rossmeislova

P Kraml

Affiliations

Soon will be listed here.

Abstract

Background/objectives: OxLDL-β2GPI complex has been suggested to have a role in the development of atherosclerosis and other inflammatory diseases. The aim of this study was to investigate the possible association of circulating oxLDL-β2GPI with obesity-induced inflammatory state of adipose tissue and related comorbidities as metabolic syndrome development.

Subjects/methods: Two cohorts of subjects were examined in the study. Cohort I: 36 women with wide range of body mass index (17-48 kg m) and metabolic status (with or without metabolic syndrome (MS); cohort II: 20 obese women undergoing a dietary intervention (DI) consisting of 1-month very-low-calorie diet, and 5 months of weight-stabilization period. Serum levels of oxLDL-β2GPI were measured by enzyme-linked immunosorbent assay. Insulin sensitivity was evaluated by hyperinsulinemic-euglycemic clamp and homeostasis model assessment of insulin resistance. mRNA expression of macrophage markers was determined in both subcutaneous (SAT) and visceral (VAT) adipose tissue in cohort I and in SAT in cohort II.

Results: Serum oxLDL-β2GPI levels were increased in obese subjects with MS compared to lean or obese without MS (obese with MS: 26.6±5.0 vs lean: 15.17±1.97, P<0.001; vs obese without MS: 16.36±2.89, P<0.05). Serum oxLDL-β2GPI correlated with MS indices (glucose, high-density lipoprotein, triglyceride and ureic acid) and with mRNA expression of macrophage markers in VAT. Weight-reducing DI decreased serum oxLDL-β2GPI levels together with lipid parameters and the mRNA expression of inflammatory markers in SAT.

Conclusions: OxLDL-β2GPI seems to be an important marker of visceral adipose tissue inflammation and possibly a factor contributing to insulin resistance and metabolic syndrome development in obese patients.

Citing Articles

The Role of Immune Cells in Moyamoya Disease.

Wang S, Jiang Q, Liu Y, Zhang X, Huang Y, Zhang H Brain Sci. 2025; 15(2).

PMID: 40002470 PMC: 11852451. DOI: 10.3390/brainsci15020137.

Overfeeding-Induced Obesity Could Cause Potential Immuno-Physiological Disorders in Rainbow Trout ().

Roh H, Park J, Kim A, Kim N, Lee Y, Kim B Animals (Basel). 2020; 10(9).

PMID: 32854279 PMC: 7552159. DOI: 10.3390/ani10091499.

References

Capel F, Klimcakova E, Viguerie N, Roussel B, Vitkova M, Kovacikova M . Macrophages and adipocytes in human obesity: adipose tissue gene expression and insulin sensitivity during calorie restriction and weight stabilization. Diabetes. 2009; 58(7):1558-67. PMC: 2699855. DOI: 10.2337/db09-0033. View

Esser N, Legrand-Poels S, Piette J, Scheen A, Paquot N . Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014; 105(2):141-50. DOI: 10.1016/j.diabres.2014.04.006. View

Kralova Lesna I, Kralova A, Cejkova S, Fronek J, Petras M, Sekerkova A . Characterisation and comparison of adipose tissue macrophages from human subcutaneous, visceral and perivascular adipose tissue. J Transl Med. 2016; 14(1):208. PMC: 4940901. DOI: 10.1186/s12967-016-0962-1. View

Arner P . Not all fat is alike. Lancet. 1998; 351(9112):1301-2. DOI: 10.1016/S0140-6736(05)79052-8. View

Liu J, Rosner M . Lipid abnormalities associated with end-stage renal disease. Semin Dial. 2006; 19(1):32-40. DOI: 10.1111/j.1525-139X.2006.00117.x. View

Sanchez-Quesada J, Vinagre I, de Juan-Franco E, Sanchez-Hernandez J, Bonet-Marques R, Blanco-Vaca F . Impact of the LDL subfraction phenotype on Lp-PLA2 distribution, LDL modification and HDL composition in type 2 diabetes. Cardiovasc Diabetol. 2013; 12:112. PMC: 3750253. DOI: 10.1186/1475-2840-12-112. View

Viardot A, Lord R, Samaras K . The effects of weight loss and gastric banding on the innate and adaptive immune system in type 2 diabetes and prediabetes. J Clin Endocrinol Metab. 2010; 95(6):2845-50. DOI: 10.1210/jc.2009-2371. View

Anderson M, Staal F, Gitler C, Herzenberg L . Separation of oxidant-initiated and redox-regulated steps in the NF-kappa B signal transduction pathway. Proc Natl Acad Sci U S A. 1994; 91(24):11527-31. PMC: 45264. DOI: 10.1073/pnas.91.24.11527. View

Mangge H, Zelzer S, Puerstner P, Schnedl W, Reeves G, Postolache T . Uric acid best predicts metabolically unhealthy obesity with increased cardiovascular risk in youth and adults. Obesity (Silver Spring). 2013; 21(1):E71-7. DOI: 10.1002/oby.20061. View

10.

Kraml P, Syrovatka P, Potockova J, Andel M . The oxidized low-density lipoprotein/β2-glycoprotein I complex is associated with abdominal obesity in healthy middle-aged men. Ann Nutr Metab. 2012; 62(1):7-13. DOI: 10.1159/000343049. View

11.

Hasunuma Y, Matsuura E, Makita Z, KATAHIRA T, Nishi S, Koike T . Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol. 1997; 107(3):569-73. DOI: 10.1046/j.1365-2249.1997.d01-948.x. View

12.

Boullier A, Bird D, Chang M, Dennis E, Friedman P, Horkko S . Scavenger receptors, oxidized LDL, and atherosclerosis. Ann N Y Acad Sci. 2002; 947:214-22; discussion 222-3. DOI: 10.1111/j.1749-6632.2001.tb03943.x. View

13.

Garg P, McClelland R, Jenny N, Criqui M, Greenland P, Rosenson R . Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: The multi ethnic study of atherosclerosis. Atherosclerosis. 2015; 241(1):176-82. PMC: 4504012. DOI: 10.1016/j.atherosclerosis.2015.05.006. View

14.

George J, Harats D, Gilburd B, Afek A, Levy Y, Schneiderman J . Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation. 1999; 99(17):2227-30. DOI: 10.1161/01.cir.99.17.2227. View

15.

Flohe L, Brigelius-Flohe R, Saliou C, Traber M, Packer L . Redox regulation of NF-kappa B activation. Free Radic Biol Med. 1997; 22(6):1115-26. DOI: 10.1016/s0891-5849(96)00501-1. View

16.

Frostegard J . Autoimmunity, oxidized LDL and cardiovascular disease. Autoimmun Rev. 2003; 1(4):233-7. DOI: 10.1016/s1568-9972(02)00059-9. View

17.

Liu J, Ren Y, Kang L, Zhang L . Oxidized low-density lipoprotein increases the proliferation and migration of human coronary artery smooth muscle cells through the upregulation of osteopontin. Int J Mol Med. 2014; 33(5):1341-7. DOI: 10.3892/ijmm.2014.1681. View

18.

Rossmeislova L, Malisova L, Kracmerova J, Tencerova M, Kovacova Z, Koc M . Weight loss improves the adipogenic capacity of human preadipocytes and modulates their secretory profile. Diabetes. 2013; 62(6):1990-5. PMC: 3661637. DOI: 10.2337/db12-0986. View

19.

Sies H, Berndt C, Jones D . Oxidative Stress. Annu Rev Biochem. 2017; 86:715-748. DOI: 10.1146/annurev-biochem-061516-045037. View

20.

Frostegard J, Haegerstrand A, Gidlund M, Nilsson J . Biologically modified LDL increases the adhesive properties of endothelial cells. Atherosclerosis. 1991; 90(2-3):119-26. DOI: 10.1016/0021-9150(91)90106-d. View